Brent Beasley, MD, a former internist and geriatrician, was diagnosed with early-onset Alzheimer's disease at age 57.[1] He underwent neuro-psychological tests, an MRI and a lumbar puncture, which showed elevated levels of tau as a biomarker of Alzheimer's disease.[1] Since November 2023, he has been taking lecanemab intravenously every two weeks for 19 months, which slows cognitive decline by 30 percent.[1] In August 2024, he felt an improvement in mental clarity.[1] Alzheimer's disease is the most common form of dementia, affecting 60 to 80 percent of dementia cases.[1] Beasley suggests phosphorylated tau217 as a sensitive and specific screening test for Alzheimer's disease in Medicare Wellness Visits because an effective treatment exists but is not currently reimbursed by Medicare.[3] The Alzheimer's Association has awarded grants totaling $5 million to develop therapies, including personalized gene therapies and a clinical trial of urolithin A in Alzheimer's.[2]